Table 2.

Clinical characteristics of patients related to exposure to MMF

	Never (n = 57)	Previous (n = 35)	Current (n = 18)	p
Age
Sex (female)	54 (96.4%)	33 (94.3%)	17 (94.4%)	0.873
Ethnic background				0.408
White	34 (60.7%)	18 (54.6%)	10 (55.6%)
Black	4 (7.14%)	6 (18.2%)	4 (22.2%)
Asian	13 (21.2%)	4 (12.1%)	3 (16.7%)
Other	5 (8.93%)	5 (15.2%)	1 (5.56%)
Disease duration	18 (8, 17)	11 (7, 17)	8 (5, 13)	0.273
ACR criteria
Malar rash	33 (58.9%)	17 (48.6%)	10 (55.6%)	0.626
Discoid rash	7 (12.5%)	5 (14.3%)	3 (16.7%)	0.900
Photosensitivity	37 (66.1%)	15 (42.9%)	7 (38.9%)	0.035
Oral ulcers	38 (67.9%)	18 (51.4%)	12 (66.7%)	0.266
Arthritis	49 (87.5%)	34 (97.1%)	14 (77.8%)	0.090
Serositis	18 (32.1%)	9 (25.7%)	6 (33.3%)	0.772
Neurological	4 (7.14%)	3 (8.57%)	1 (5.56%)	0.921
Renal	21 (37.5%)	11 (31.4%)	12 (67.7%)	0.038
Haematological	30 (53.6%)	22 (62.9%)	11 (61.1%)	0.651
Immunological	39 (69.6%)	27 (77.1%)	15 (83.3%)	0.460
ANA	49 (87.5%)	32 (91.4%)	15 (83.3%)	0.678
SLICC-DI	0 (0, 1)	0 (0, 2)	0 (0, 1)	0.862
Current prednisolone	46 (83.6%)	31 (88.6%)	17 (94.4%)	0.470
Daily prednisolone dose (mg/day)	10 (5–20)	10 (7.5–20)	10 (10–20)	0.280
SLEDAI score	10 (5.5–13.5)	6 (4–10)	10 (6–14)	0.051
Active disease (BILAG A/B)
Constitutional (A or B)	6 (10.5%)	1 (2.86%)	1 (5.56%)	0.371
Mucocutaneous (A or B)	33 (57.9%)	10 (28.6%)	8 (44.4%)	0.023
Neuropsychiatric (A or B)	4 (7.02%)	4 (11.4%)	2 (11.1%)	0.735
Musculoskeletal (A or B)	35 (61.4%)	10 (28.6%)	6 (33.3%)	0.004
Cardiorespiratory (A or B)	8 (14.0%)	2 (5.71%)	3 (16.7%)	0.382
Gastrointestinal (A or B)	3 (5.26%)	0	2 (11.1%)	0.172
Ophthalmic (A or B)	2 (3.51%)	2 (5.71%)	1 (5.56%)	0.863
Renal (A or B)	19 (33.3%)	9 (25.7%)	11 (61.1%)	0.034
Haematological (A or B)	0	2 (5.71%)	1 (5.56%)	0.190
Low C3/C4	29 (51.2%)	11 (44.0%)	13 (72.2%)	0.173
Raised dsDNA	24 (42.9%)	12 (48.0%)	13 (72.2%)	0.094